摘要
目的对紫杉醇联合卡铂治疗卵巢癌的临床治疗效果进行研究和分析。方法选取2018年9月—2020年9月来该院接受治疗的卵巢癌患者120例作为研究对象,采用随机分组法将参与研究的所有患者分为对照组和研究组,各60例。予以对照组患者卡铂化疗疗法,予以研究组患者紫杉醇联合卡铂化疗疗法,以患者的临床治疗有效率作为该次研究的检测指标,对两组患者不同疗法的临床治疗效果以及CA125指标变化进行对比。结果研究组患者的临床治疗总有效率为93.3%,显著高于对照组的73.3%,差异有统计学意义(χ^(2)=8.640,P<0.05)。两组患者在治疗前CA125指标差异无统计学意义(P>0.05),治疗后研究组患者相关指标低于对照组,差异有统计学意义(P<0.05),其中对照组治疗后CA125指标为(42.1±5.3)kU/L,研究组则为(14.8±4.5)kU/L,差异有统计学意义(t=29.119,P<0.05)。结论相比单纯的卡铂化疗疗法,患者经紫杉醇联合卡铂化疗疗法后的临床治疗效果更好,而且还能够从根本上改善患者CA125指标,因此,紫杉醇联合卡铂化疗疗法值得在卵巢癌的临床治疗中应用和推广。
Objective To study and analyze the clinical therapeutic effect of paclitaxel combined with carboplatin in the treatment of ovarian cancer.Methods A total of 120 ovarian cancer patients who came to the hospital for treatment from September 2018 to September 2020 were selected as the research objects.All patients participating in the study were divided into a control group and an the study group by a random grouping method,with 60 patients in each group.Patients in the control group were given carboplatin chemotherapy,and the patients in the the study group were given paclitaxel combined with carboplatin chemotherapy.The clinical treatment efficiency of the patients was used as the detection index of this Study,and the clinical treatment effects of different therapies and the changes in CA125 index of the two groups of patients were compared.Results The total effective rate of clinical treatment in the the study group was 93.3%,which was significantly higher than the control group's 73.3%,the difference was statistically significant(χ^(2)=8.640,P<0.05).The CA125 index of the two groups of patients were not statistically significantly different before treatment(P>0.05).After treatment,the relevant indexes of the the study group were lower than those of the control group,the difference was statistically significant(P<0.05).The CA125 index of the control group after treatment was(42.1±5.3)kU/L,the the study group was(14.8±4.5)kU/L,the difference was statistically significant(t=29.119,P<0.05).Conclusion Compared with pure carboplatin chemotherapy,the clinical treatment effect of patients with paclitaxel combined with carboplatin chemotherapy is better,and it can also fundamentally improve the patient's CA125 index.Therefore,paclitaxel combined with carboplatin chemotherapy is worthy of application and promotion in the clinical treatment of ovarian cancer.
作者
王云
WANG Yun(Department of Gynecology,Feicheng Hospital,Shandong First Medical University,Tai'an,Shandong Province,271600 China)
出处
《系统医学》
2021年第17期139-141,共3页
Systems Medicine
